{"url":"https://economictimes.indiatimes.com/tech/technology/boston-based-bicara-therapeutics-goes-public-lists-on-nasdaq/articleshow/113711740.cms","title":"With IPO, have the capital and resources for clinical studies: Bicara CEO","description":"​​As per Reuters, shares of Bicara Therapeutics surged nearly 46% in their debut on September 13, giving the TPG-backed cancer therapy developer a market value of $1.29 billion. Its shares opened at $26.25, compared with the offer price of $18, the news agency said. Bicara raised $315 million by selling 17.5 million shares in its initial public offering, after increasing the size of its offer twice, it said.","content":"Claire Mazumdar, chief executive of Boston-based Bicara Therapeutics, said the company has sufficient funds and resources to carry out clinical studies after its recent $315 million initial public offering (IPO). Claire is the niece of Biocon chief Kiran Mazumdar Shaw.The TPG-backed cancer therapy developer became a publicly listed company after getting listed on Nasdaq on September 13. Bicara is a clinical-stage biopharmaceutical company for bifunctional therapies for patients with solid tumors.The IPO saw Bicara sell 17.5 million shares after increasing the size of its offer twice.The company's lead drug, ficerafusp alfa, is currently in an early-stage study in the US to treat a type of head and neck cancer in combination with Merck's Keytruda. As per Reuters, it plans to use part of the IPO proceeds to fund its mid-to-late stage study, which is expected to start later this year or early 2025.During an opening bell ceremony on Wednesday, Claire said, \"Today has been incredibly exciting and a humbling moment for all of us at Bicara as we celebrate this pivotal milestone of becoming a public company...This reaffirms our commitment to improving outcomes for cancer patients. From day one Bicara was founded on the belief that innovative science with roots in India's emerging and dynamic biotech sector has the potential to save lives.\"","cleaned_content":"claire mazumdar chief executive of boston based bicara therapeutics said the company has sufficient funds and resources to carry out clinical studies after its recent \u003cTHREE_HUNDRED\u003e million initial public offering ipo claire is the niece of biocon chief kiran mazumdar shaw the tpg backed cancer therapy developer became a publicly listed company after getting listed on nasdaq on september \u003cONE_TEN\u003e bicara is a clinical stage biopharmaceutical company for bifunctional therapies for patients with solid tumors the ipo saw bicara sell \u003cONE_TEN\u003e million shares after increasing the size of its offer twice the companys lead drug ficerafusp alfa is currently in an early stage study in the us to treat a type of head and neck cancer in combination with mercks keytruda as per reuters it plans to use part of the ipo proceeds to fund its mid to late stage study which is expected to start later this year or early \u003cTWO_THOUSAND\u003e during an opening bell ceremony on wednesday claire said today has been incredibly exciting and a humbling moment for all of us at bicara as we celebrate this pivotal milestone of becoming a public company this reaffirms our commitment to improving outcomes for cancer patients from day one bicara was founded on the belief that innovative science with roots in indias emerging and dynamic biotech sector has the potential to save lives","timestamp":"2024-09-26T23:37:00+05:30","market_timestamp":"2024-09-27T09:15:00+05:30","off_market_hours":true}